跳至主要内容
临床试验/NCT03609723
NCT03609723已完成不适用

Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 2,433 人开始时间: 2010年6月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,433
试验地点
1
主要终点
assessment of cardial biomarkers as high sensitive troponin T (hs-TrT), Creatinkinase (CK) and Creatinkinase myocardial type (CK-MB)

研究概览

简要总结

A patient group receiving a novel cardioplegic formula with MPS ® (Myocardial protection system) and using the MiECC (Minimal extracorporeal circulation system) when undergoing coronary artery bypass grafting is compared to a retrospective patient group undergoing Off-pump coronary artery bypass grafting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • CABG using MPS® or OPCABG

排除标准

  • use of other colloid solution than Cardioplexol ® for MPS®
  • other inventions than CABG
  • myocardial infarction <7 days before CABG
  • patients denial of data use

结局指标

主要结局

assessment of cardial biomarkers as high sensitive troponin T (hs-TrT), Creatinkinase (CK) and Creatinkinase myocardial type (CK-MB)

时间窗: perioperative during hospital stay for CABG

high sensitive troponin T (hs-TrT), Creatinkinase, (CK) Creatinkinase myocardial type (CK-MB)

次要结局

  • mortality(30 days after CABG)
  • need for intensive care unit(perioperative during hospital stay for CABG)
  • occurence of dysrhythmia(perioperative during hospital stay for CABG)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验